Makaleler
Tümü (7)
SCI-E, SSCI, AHCI (4)
SCI-E, SSCI, AHCI, ESCI (5)
ESCI (1)
Scopus (6)
TRDizin (2)
2022
20221. Is sitagliptin effective for the treatment of COVID-19?
MEMİŞ H., ÇAKIR A., DURMUŞ M., Gok S., Bahcecioglu O. F.
EUROPEAN JOURNAL OF HOSPITAL PHARMACY
, cilt.29, sa.6, 2022 (SCI-Expanded, Scopus)
2022
20222. Your publication: COVID-19 PANDEMİSİ DÖNEMİNDE GÖĞÜS HASTALIKLARI POLİKLİNİĞİ’NE BAŞVURAN HASTALARDA UYGUN İNHALER TEKNİĞİ VE ANKSİYETE İLİŞKİSİNİN DEĞERLENDİRİLMESİ: PROSPEKTİF KESİTSEL BİR ÇALIŞMA
Durmuş M., Gök S., Bahçecioğlu Ö. F., Gün Z. Ü., Hacıevliyagil S. S.
ANKARA UNIVERSITESI ECZACILIK FAKULTESI DERGISI , cilt.46, sa.3, ss.793-804, 2022 (Scopus, TRDizin)
2021
20213. The safety profile of favipiravir in COVID-19 patients with severe renal impairment
Gok S., Bahcecioglu O. F., Durmus M., GÜN Z. Ü., ERSOY Y., AYTEMUR Z. A., et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
, cilt.75, sa.12, 2021 (SCI-Expanded, Scopus)
2021
20214. Is there any difference between busulfan-cyclophosphamide and cyclophosphamide-busulfan in patients underwent allogeneic transplantation?
Bahcecioglu O. F., Gok S., Durmus M., SARICI A.
HEMATOLOGY TRANSFUSION AND CELL THERAPY
, cilt.43, sa.4, ss.527-528, 2021 (ESCI, Scopus)
2021
20215. Daptomycin in combination with rosuvastatin induced blood creatine phosphokinase elevation
Durmus M., Bahcecioglu O. F., Gok S.
EUROPEAN JOURNAL OF HOSPITAL PHARMACY
, cilt.28, sa.4, ss.234-236, 2021 (SCI-Expanded, Scopus)
2021
20216. Is it safe to use remdesivir in combination with a combined p-glycoprotein and CYP3A4 inhibitor?
Bahcecioglu O. F., Gok S., Durmus M.
EUROPEAN JOURNAL OF HOSPITAL PHARMACY
, cilt.28, sa.2, 2021 (SCI-Expanded, Scopus)
2019
20197. Aril(alkil)azol türevlerinin sentezi ve biyolojik aktiviteleri
DURMUŞ M., BARUT B., SELLİTEPE H. E., ÖZEL A., DOĞAN İ. S.
Mersin Üniversitesi Sağlık Bilimleri Dergisi , ss.60-71, 2019 (TRDizin)